KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBT Margin (2016 - 2025)

Historic EBT Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 16.01%.

  • Acadia Pharmaceuticals' EBT Margin rose 5100.0% to 16.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.14%, marking a year-over-year increase of 114200.0%. This contributed to the annual value of 26.94% for FY2024, which is 339700.0% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported EBT Margin of 16.01% as of Q3 2025, which was up 5100.0% from 15.2% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' EBT Margin peaked at 62.05% during Q4 2024, and registered a low of 97.52% during Q1 2022.
  • For the 5-year period, Acadia Pharmaceuticals' EBT Margin averaged around 11.18%, with its median value being 11.24% (2021).
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by -351800bps in 2022, then soared by 595800bps in 2023.
  • Acadia Pharmaceuticals' EBT Margin (Quarter) stood at 32.81% in 2021, then rose by 9bps to 29.92% in 2022, then soared by 157bps to 17.18% in 2023, then soared by 261bps to 62.05% in 2024, then plummeted by -74bps to 16.01% in 2025.
  • Its EBT Margin was 16.01% in Q3 2025, compared to 15.2% in Q2 2025 and 11.38% in Q1 2025.